What would you like to know about Â鶹AV Pharmaceutics?
Editor-in-Chief: Yvonne Perrie
Impact factor: n/a
Gold open access, APCs currently waived
Time to first decision (peer-reviewed only): 47.0 days***
Time to first decision (all decisions): 15 days**
Indexed in Directory of Open Access Journals (DOAJ)
How can chemistry help build a healthier world?
Chemistry is at the centre of our existence and offers transformative solutions to many global challenges, including health. Â鶹AV Pharmaceutics acknowledges how chemistry and related disciplines can make a big difference. This impactful journal provides you with a platform to publish crucial research on pharmaceutics.
This is an area of technical opportunity. We are interested in papers that cover emerging technologies and techniques in pharmaceutics, including drug delivery, precision medicine, and enhanced drug targeting. If your research pushes the boundaries of current thinking, then we want to hear from you.
The publications in Â鶹AV Pharmaceutics have the potential to drive real change in worldwide health. Our gold open access policy elevates this potential, making sure that everyone around the planet can access and benefit from our publications. We are also covering article processing charges until mid-2026, so you can publish with us for free. Let’s get started.
Introducing our Editor-in-Chief
Â鶹AV Pharmaceutics will provide a platform for researchers to showcase their best work in this field and contribute to the advancement of Pharmaceutics. I look forward to promoting this journal and its published research to the community.
Journal scope
Â鶹AV Pharmaceutics is a new gold open access journal leading the way in the field of Pharmaceutics. This journal publishes research focused on formulating a drug into a medicine, with the intention of achieving controllable drug delivery with high efficacy.
Research published in Â鶹AV Pharmaceutics promotes step-change science in the field of Pharmaceutics, and, as such, all submissions must show clear innovation, be scientifically sound, and have a significant impact on the field. Research sharing new scientific findings from across the areas of chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery are all welcomed.
Topics include but are not limited to:
- Formulation and design of medicines
- Design and characterization of correct dosage forms
- Physicochemical and biological properties of drugs and their carriers
- Drug delivery devices and their mechanisms of release
See who's on the team
Meet Â鶹AV Pharmaceutics's Editor-in-Chief and board members.
Editorial members
Editor-in-chief
University of Strathclyde, UK
Associate Editor
University of Strathclyde, UK
Associate Editor
China Pharmaceutical University, China
Associate Editor
Florida International University, USA
Associate Editor
Technion - Israel Institute of Technology, Israel, & Houston Methodist Academic Institute, USA
Editorial Board Member
National Institute of Pharmaceutical Education and Research (NIPER), India
Laura Fisher, Executive Editor, ORCID:
Sarah Rainford, Deputy Editor
Anna Moore, Editorial Production Manager
Namita Datta, Assistant Editor
Jie Gao, Assistant Editor
Anoushka Handa, Assistant Editor
Kate Jones, Assistant Editor
Patrick de Jongh, Assistant Editor, ORCID:
Claire Mitchell, Assistant Editor, ORCID:
Chloe Wallace, Assistant Editor
Karina Webster, Editorial Assistant
Natalie Ford, Publishing Assistant
Neil Hammond, Publisher, ORCID:
Yahya Choonara, University of the Witwatersrand, South Africa
Sara Cordeiro, Leicester School of Pharmacy, De Montfort University, UK
Emily Day, University of Delaware, USA
Anthony J. Hickey, University of North Carolina at Chapel Hill, USA
Twan Lammers, RWTH Aachen University Clinic, Germany
Dimitrios Lamprou, Queens University Belfast, Northern Ireland
Andrew Lewis, Quotient Sciences, UK
Eliana Lima, Universidade Federal de Goias, Brazil
Naved I. Malek, Sardar Vallabhbhai National Institute of Technology, India
Scott Mitchell, Aragón Nanoscience and Materials Institute (INMA), Spain
Priyabrata Mukherjee, University of Oklahoma Health Sciences Center, USA
Wilson Poon, University of Texas at El Paso, USA
Faisal Raza, Shanghai Jiao Tong University, China
Avi Schroeder, Technion - Israel Institute of Technology, Israel
Lingling Shen, Discovery Sciences, Novartis Biomedical Research, USA
Audra Stinchcomb, School of Pharmacy, University of Maryland, USA
Raju Vivek, Bharathiar University, India
Stefan Wilhelm, University of Oklahoma, USA
Author Guidelines
For general guidance on preparing an article please visit our Prepare your article page, the content of which is relevant to all our journals. Please note that Â鶹AV Pharmaceutics does not require authors to submit using a specific template, but there are templates available if you wish to use them.
To learn more about the Â鶹AV's policies and processes, including licensing, experimental data guidelines, peer review and formatting, please refer to our Resources for authors and Experimental data guidelines pages.
Peer review and editorial process
All articles published in Â鶹AV Pharmaceutics are subject to external peer review by anonymised experts in the field and all manuscripts submitted are handled by a team of internationally recognised Associate Editors, who are all practicing scientists in the field.
The peer review for all articles submitted to the journal consists of the following stages:
Phase 1: Your manuscript is initially assessed by an associate editor to determine its suitability for peer review.
Phase 2: If the manuscript passes the initial assessment process, the associate editor solicits recommendations from at least two anonymous reviewers who are experts in the field. They will provide a report along with their recommendation.
Phase 3: The associate editor handling your manuscript makes a decision based on the reviewer reports received. In the event that no clear decision can be made, another reviewer will be consulted.
Â鶹AV Pharmaceutics is committed to a rigorous peer review process and expert editorial oversight for all published content. Please refer to our processes and policies for full details including our appeals procedure.
Transparent peer review
To support increased transparency, we offer authors the option of transparent peer review, where the editor’s decision letter, reviewers’ comments and authors’ response for all versions of the manuscript will be published alongside the article under an . Reviewers are anonymous unless they choose to sign their report.
Find out more about our transparent peer review policy.
Publication frequency
Articles accepted for publication in Â鶹AV Pharmaceutics are published online with citeable DOIs as Advance Articles after they are edited and typeset. Articles are then assigned page numbers and published in an issue. Issues of Â鶹AV Pharmaceutics are published every other month.
.
Ethical Requirements
Â鶹AV Pharmaceutics authors, editors, reviewers and published works are required to uphold the Â鶹AV’s ethical standards. The Â鶹AV is a member of the and our ethical standards follow COPE’s and . In cases where these guidelines are breached or appear to be so, the Â鶹AV will consult with COPE guidelines and act accordingly.
When a study involves the use of live animals or human subjects, authors must include in the 'methods/experimental' section of the manuscript a statement that all experiments were performed in compliance with the author’s institute’s policy on animal use and ethics; where possible, details of compliance with national or international laws or guidelines should be included. The statement must name the institutional/local ethics committee which has approved the study; where possible, the approval or case number should be provided. A statement that informed consent was obtained for any experimentation with human subjects is required. Reviewers may be asked to comment specifically on any cases in which concerns arise.
For further guidance on author responsibilities and code of conduct, which apply to Â鶹AV Pharmaceutics and to all manuscripts submitted to Â鶹AV journals, please visit our author hub.
Open Access
As a gold open access journal, Â鶹AV Pharmaceutics can maximise the potential and visibility of your publications. Our articles are free to read, access and cite by anyone around the world. We are also covering all article processing charges until mid-2026, so you can publish with us for free.
We offer Â鶹AV Pharmaceutics authors a choice of two Creative Commons licences: CC BY or CC BY NC. Publication under these licences means that authors retain the copyright of their article, but users are allowed to read, download, copy, distribute, print, search, or link to the full texts of articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Read our open access statement for further information.
All published articles are deposited with LOCKSS, CLOCKSS, Portico and the British Library for archiving.
Dive into the benefits of open access publishing:
Find out more about open access publishing routes
Subscription information
Â鶹AV Pharmaceutics is fully gold open access – articles can be downloaded free from the website with no barriers to access.
Online only: ISSN 2976-8713
Copyright
Copyright is retained by authors when an open access licence is accepted, as with our standard licence to publish agreement. Full and accurate attribution to the original author is required for any re-use of the work. Find out more about copyright, licences and re-use permission.
**The median time from submission to first decision including manuscripts rejected without peer review from the previous calendar year
***The median time from submission to first decision for peer-reviewed manuscripts from the previous calendar year
Get email alerts about Â鶹AV Pharmaceutics
For the latest editorial board news, scope details and announcements, sign up for news and issue alerts by using the form below. For any other queries, please get in touch using the contact us form on this page.
Contact us
- Email:
- send us an email